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Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous-cell carcinoma that occurs in the epithelial
lining of the nasopharynx. Nasopharyngeal carcinoma has a geographically well-deﬁned distribution worldwide,
with the highest prevalence in China, Southeast Asia, and Northern Africa. Symptoms of nascent NPC may be unapparent or trivial, with diagnosis based on the histopathology of biopsied tissue following endoscopy of the nasopharynx. The tumor node metastasis (TNM) staging system is the benchmark for the prognosis of NPC and
guides treatment strategy. However, there is a consensus that the TNM system is not sufﬁciently speciﬁc for
the prognosis of NPC, as it does not reﬂect the biological heterogeneity of this tumor, making another biomarker
for the detection of NPC a priority. We have previously reported on different approaches for microRNA (miRNA)
biomarker discovery for Formalin Fixed Parafﬁn Embedded (FFPE) NPC tissue samples by both a targeted (microarray) and an untargeted (small RNA-Seq) discovery platform. Both miRNA discovery platforms produced similar
results, narrowing the miRNA signature to 1–5% of the known mature human miRNAs, with untargeted (small
RNA-Seq approach) having the advantage of indicating “unknown” miRNAs associated with NPC. Both miRNA
proﬁles strongly associated with NPC, providing two potential discovery platforms for biomarker signatures for
NPC. Herein, we provide a detailed description of the methods that we used to interrogate FFPE samples to
discover biomarkers for NPC.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Speciﬁcations
Organism/cell line/tissue
Sex
Sequencer or array type
Data format
Experimental factors
Experimental features
Consent
Sample source location

Homo sapiens
5 males 3 females
Agilent human miRNA microarray
Illumina Genome Analyzer IIx
Raw and processed
Tumor vs. adjacent tissue in FFPE
Biomarker analysis in NPC FFPE tissue between
tumor and control nasopharynx.
IRB approved
Washington DC, United States

⁎ Corresponding author at: Department of Microbiology, Immunology and Tropical
Medicine, School of Medicine & Health Sciences, The George Washington University,
2300 Eye Street, NW, Washington DC, 20037, USA. Fax: +1 202 994 2913.
E-mail address: jordanp@gwu.edu (J.L. Plieskatt).

Microarray deposited data can be found here: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE46172
RNA-Seq deposited data can be found here: http://www.ncbi.nlm.
nih.gov/sra/?term=SRP029599
Experimental design, materials and methods
Experimental cases
Case and control tissue including sample characteristics are presented
in Table 1 (and in detail in [1]). In brief, four formalin ﬁxed parafﬁnembedded (FFPE) tissues from cases of histologically conﬁrmed nonkeratinizing NPC and four FFPE cases of normal nasopharyngeal tissue

http://dx.doi.org/10.1016/j.gdata.2014.08.005
2213-5960/© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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were obtained from the biological repository in the Department of Pathology of The George Washington University Hospital, Washington,
DC. Tissue sections from FFPE were reviewed by two independent
pathologists (E.M. and S.E.) to conﬁrm the diagnosis as shown in [1].
FFPE preparation, hematoxylin and eosin (H&E) staining, and representative images have also been previously reported [1]. It should also be
noted that the SRA project submission contains four additional samples
(Accession: SRX345915, SRX345913, SRX345913 and SRX345909).
These samples reference a survey of serum pools from NPC positive
and control individuals discussed in [1] but not further referenced
herein.
RNA isolation
Total RNA was isolated from 2 × 10 μm sections from each FFPE case
using the miRNeasy FFPE kit (Qiagen) [1]. RNA concentration, purity,
and integrity (RIN) were determined by spectrophotometry (Nanodrop
1000) and the Agilent 2100 Bioanalyzer using the Agilent RNA 6000
Nano and small RNA kits. Puriﬁed RNA was stored at b−50 °C.
Yields of total RNA derived from FFPE were approximately 100 ng/μm
with 260/280 and 260/230 ratios of ~2.0 and ~1.9, respectively. Analysis
on the Agilent Bioanalyzer indicated that the samples were enriched for
small RNA species with integrity (RNA Integrity Number or RIN) values
of two to three. Though typically indicative of RNA degradation, the
robustness of miRNAs in these FFPE tissue [2] and reports from other
groups [3] that RIN values have negligible effect on miRNA results
enabled us to consider this puriﬁed RNA suitable for further analysis
by microarray and RNA sequencing.
Microarray, data normalization and analysis
All eight samples underwent analysis via microarray (Table 1). Total
RNA isolated from each FFPE case was labeled and hybridized to an
Agilent human miRNA microarray (miRBase Release 16.0) and scanned
[1]. The intensities of each sample were transferred to digital data and
log2 transformed using Agilent Feature Extraction (V.10.7). Raw data
ﬁles in text (.txt) format were analyzed with Agilent GeneSpring

software (GX 12.6) [4]. A total of 1205 human and 144 human viral
microRNAs were used from miRBase v16.0.
To analyze the differentially expressed miRNAs, quantile normalization was performed to standardize these data across the samples. Raw
data (thresholded and log base 2 transformed) were ﬁltered by expression values (20.0–336133.0) with at least two out of the eight samples
having values within the cut-off range to remove very low signal values
and background inﬂuence. The four tumor samples were grouped and
analyzed against the four control samples by unpaired Student's t-test
with a p-value cut-off of 0.05 (p-value obtained by Asymptotic analysis)
and a fold-change cut-off of 2.0. Hierarchical clustering was then
performed [1] using the Euclidean distance metric and Centroid linkage
rule. We identiﬁed 35 signiﬁcantly dysregulated miRNAs, including four
Epstein–Barr Virus (EBV) miRNAs and 31 human miRNAs (13 downregulated and 18 up-regulated) [1]. These analyses were conducted
again for this manuscript to verify their reproducibility. In addition,
the miRNA signatures were compared to the recently released miRBase
(v 19.0) with its up-date the miRNA nomenclature (Table 2) than in the
original publication of these data, which used miRBase (v 16.0) [1].
Signiﬁcance analysis was completed using GeneSpring [4] as
detailed below:
1) A new project was created, followed by a new experiment, and miRNA
was selected for analysis type, followed by the data import wizard for
workﬂow type.
2) In New miRNA Experiment Steps, the raw intensity ﬁles were
uploaded. The selected technology was set to 31181_v16_0 and no
baseline transformation was performed. The threshold raw signals
were set to 1.0 and quantile was chosen as the normalization algorithm along.
3) In the Experiment Setup, the samples were grouped into four tumor
and four control cases under the Experiment Grouping option.
While further interpretations may be created depending on analysis
requirements, in this case experimental parameters “tumor/control”
(categorical) were set up.
The condition tumor and control were selected and Non-Averaged for
the Average Over Replicates in Conditions. Detected and Not Detected
were selected and Compromised in Use Measurements Flagged.

Table 1
List of the raw data ﬁles deposited to NCBI GEO and SRA with accession numbers. Further details on the FFPE sample set in [1] with histological type, TNM staging [9] and WHO
classiﬁcation [10].

a

b

a

b

a,b

Denotes those from the same patient (i.e. paired NPC/Control tissue samples).
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Table 2
Microarray miRNA expression analysis between tumor and control NPC FFPE tissue using unpaired Student's t-test (p-value b0.05 and fold-change N2.0). In this repeated analysis by
GeneSpring updated nomenclature found in miRBase v19.0 was utilized to update the sample set found in [1]. Thirty-ﬁve miRNAs were dysregulated comprising four EBV speciﬁc miRNAs.
Systematic name

FC

Log FC

Regulation

Active sequence

Chromosome

miRBase accession no.

ebv-miR-BART4-3p
ebv-miR-BART5-5p
ebv-miR-BART6-3p
ebv-miR-BART6-5p
hsa-let-7b-5p
hsa-miR-100-5p
hsa-miR-106b-5p
hsa-miR-125b-5p
hsa-miR-1260a
hsa-miR-1274a_v16.0
hsa-miR-1274b_v16.0
hsa-miR-1275
hsa-miR-130b-3p
hsa-miR-133b
hsa-miR-141-3p
hsa-miR-149-5p
hsa-miR-15b-5p
hsa-miR-17-3p
hsa-miR-17-5p
hsa-miR-18a-5p
hsa-miR-195-5p
hsa-miR-196b-5p
hsa-miR-199a-3p
hsa-miR-199b-5p
hsa-miR-203a
hsa-miR-20a-5p
hsa-miR-221-3p
hsa-miR-25-3p
hsa-miR-3138
hsa-miR-3651
hsa-miR-3663-3p
hsa-miR-451a
hsa-miR-486-5p
hsa-miR-497-5p
hsa-miR-93-5p

99.86
69.01
92.81
99.86
−2.09
−2.92
2.13
−2.20
2.27
2.94
2.44
−3.38
2.18
−688.84
4.93
7.11
2.05
8.90
2.44
13.99
−6.00
47.26
−2.65
−3.96
41.64
2.18
4.19
2.28
−2.31
3.06
−2.55
−6.12
−3.90
−5.17
3.28

6.64
6.11
6.54
6.64
−1.06
−1.55
1.09
−1.14
1.18
1.56
1.29
−1.76
1.12
−9.43
2.30
2.83
1.03
3.15
1.29
3.81
−2.59
5.56
−1.41
−1.99
5.38
1.13
2.07
1.19
−1.21
1.62
−1.35
−2.61
−1.96
−2.37
1.71

Up
Up
Up
Up
Down
Down
Up
Down
Up
Up
Up
Down
Up
Down
Up
Up
Up
Up
Up
Up
Down
Up
Down
Down
Up
Up
Up
Up
Down
Up
Down
Down
Down
Down
Up

ACACCTGGTGCCTAC
CGATGGGCAGCTATA
TCTAAGGCTAGTCCGAT
CCTATGGATTGGACCAA
AACCACACAACCTACTACC
CACAAGTTCGGATCTACGG
ATCTGCACTGTCAGCAC
TCACAAGTTAGGGTCTC
TGGTGGCAGAGGTGG
TGGCGCCTGAACAG
TGGCGCCCGAACA
GACAGCCTCTCCCC
ATGCCCTTTCATCATTGC
TAGCTGGTTGAAGGGGACC
CCATCTTTACCAGACAG
GGGAGTGAAGACACGGAG
TGTAAACCATGATGTGCTGC
CTACAAGTGCCTTCAC
CTACCTGCACTGTAAGC
CTATCTGCACTAGATGCA
GCCAATATTTCTGTGCTGC
CCCAACAACAGGAAACTACC
TAACCAATGTGCAGACTACT
GAACAGATAGTCTAAACACTGG
CTAGTGGTCCTAAACATT
CTACCTGCACTATAAGCAC
GAAACCCAGCAGACAATGT
TCAGACCGAGACAAGTGC
ACTCCCTCTACCTCACT
TCATGTACCAGCGACC
GCGCCCGGCCT
AACTCAGTAATGGTAACGGTTT
CTCGGGGCAGCTCA
ACAAACCACAGTGTGCTG
CTACCTGCACGAACAG

–
–
–
–
chr22
chr11
chr7
chr11
chr14
chr5
chr19
chr6
chr22
chr6
chr12
chr2
chr3
chr13
chr13
chr13
chr17
chr7
chr1
chr9
chr14
chr13
chrX
chr7
chr4
chr9
chr10
chr17
chr8
chr17
chr7

MIMAT0009204
MIMAT0003413
MIMAT0003415
MIMAT0003414
MIMAT0000063
MIMAT0000098
MIMAT0000680
MIMAT0000423
MIMAT0005911
MIMAT0005927
MIMAT0005938
MIMAT0005929
MIMAT0000691
MIMAT0000770
MIMAT0000432
MIMAT0000450
MIMAT0000417
MIMAT0000071
MIMAT0000070
MIMAT0000072
MIMAT0000461
MIMAT0001080
MIMAT0000232
MIMAT0000263
MIMAT0000264
MIMAT0000075
MIMAT0000278
MIMAT0000081
MIMAT0015006
MIMAT0018071
MIMAT0018085
MIMAT0001631
MIMAT0002177
MIMAT0002820
MIMAT0000093

4) Quality control: The correlation coefﬁcient value of all samples
was N 0.7 and therefore all the samples were used in further analysis.
Further, 3D Principle Components Analysis (PCA) scores and plotting were used to determine any association among the samples
(Fig. 1). It was noted that paired samples did not exhibit more significant clustering than non-paired (NPC/Control tissue) in the analysis
(Fig. 1 and Hierarchical clustering [1]). In Filter by Expression, the
right entity and interpretation were selected and ﬁltered by raw
data value. The lower cut-off value of the interest range was set to
20 and at least two out of eight samples had values within this range.
5) In Analysis, the condition was set as tumor versus control, tested by
t-test unpaired, and an asymptotic p-value was computed without
correction. The fold change cut-off was N2.0 and analyzed under
pairs of conditions with tumor compared to control. Hierarchical
clustering analysis of differentially expressed genes from all samples
was conducted on both entities and the conditions by normalized intensity values using Euclidean distance metric and Centroid linkage
rule.

using the TruSeq Small RNA Sample Kit (Illumina). Libraries were
subjected to quality control prior to sequencing using an Agilent
2100 BioAnalyzer and concentration determination using PicoGreen
(Invitrogen). The Illumina Genome Analyzer IIx was used to perform
the sequencing by Expression Analysis, A Quintiles Company (Durham,
NC).

Small RNA sequencing
Small RNA sequencing was performed on ﬁve of the same samples
used in microarray analysis (Table 1) of the three samples used in the
previous analysis (control samples 341E and 11311E and tumor sample
341B) omitted due to the exhaustion of total RNA puriﬁed from the
small tissue areas available for the study. Total RNA derived from the
FFPE was subjected to Ribo-Zero Pretreatment using Ribo-Zero rRNA
Removal Kit (Epicentre) as described by the manufacturer and in [1]. Library preparation and sequencing have been described in further details
in [1]. Brieﬂy, Illumina libraries were constructed from 1 μg of total RNA

Fig. 1. 3D principal components analysis (PCA). PCA analysis of FFPE samples analyzed via
microarray. Control FFPE tissue is denoted by red circles and NPC FFPE tissue is denoted by
blue. No signiﬁcant clustering was observed.
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Table 3
Total reads derived from small RNA-Seq of ﬁve FFPE samples. Total numbers of reads mapped to miRNA are reported.
Sample ID

Type

Total reads

miRNA mapped

Unmapped reads

%mapped

08-S-6658Aa
04-S-6103A
12-S-432A
08-S-6658Ca
05-S-5264-F

Tumor
Tumor
Tumor
Control
Control
Total

5,609,415.00
4,338,399.00
5,354,631.00
6,265,846.00
6,533,346.00
28,101,637.00

2,569,276.00
2,258,744.00
3,236,216.00
3,755,819.00
4,262,886.00
16,082,941.00

3,040,139.00
2,079,655.00
2,118,415.00
2,510,027.00
2,270,460.00
12,018,696.00

46%
52%
60%
60%
65%
57%

a

Denotes from the same patient (i.e. paired NPC/Control tissue samples).

Sequencing processing: alignment, mapping and annotation
Initial processing was performed using both FastqMcf and FastQC
both of which can be accessed at http://code.google.com/p/ea-utils/
wiki/FastqMcf and http://www.bioinformatics.babraham.ac.uk/projects/
fastqc.

Fig. 2. RNA-sequencing output of ﬁve NPC FFPE samples. (A) Biological coefﬁcient of variation reported against average log CPM. Red common trend line indicates the BCV of 67%.
(B) logFC reported versus average log CPM. Log fold change of two is indicated by bracketed blue lines. Red dots indicate human miRNAs identiﬁed as signiﬁcant (p value b0.05).

After adaptor removal and quality ﬁltering, ~ 28 million reads
were aligned to the human (UCSC hg19) and Human herpes virus 4
(Epstein–Barr virus or EBV) genome (NCBI NC_007605.1) and miRNA
counts generated for each sample [1]. Both miRDeep 2.0.0.5 [5] and
miRExpress 2.0 [6] were used to generate counts, and each provided
comparable results, with over 50% of the reads mapping to miRNAs in
either the human or EBV genomes (Table 3). Identiﬁcation of known
miRNAs was based on miRBase Release 19 [7], with an alignment identity of 1%, a tolerance range of 4, and a similarity threshold of 0.8 [1]. In
total, using miRDeep and miRExpress, 984 and 847 human and EBV
miRNAs were identiﬁed, respectively, with a count per million greater
than one in at least two of the samples.
Using EdgeR [8], a binomial distribution was used to compare the independent analyses from miRDeep and miRExpress [1]. The biological
coefﬁcient of variation (BCV) was used to estimate the variability across
the dataset and plotted via the plotBCV function (Fig. 2A), with a
common dispersion of 67% indicating a relatively high dispersion of
gene expression levels. Given that this was an observational study on independent NPC cases using NPC tumors of different histological grades,
such a value would not be considered atypical. Using the function
plotsmear in EdgeR, log-fold changes were plotted against log-cpm
(Fig. 2B). Using EdgeR, 99 dysregulated miRNAs were identiﬁed in
NPC tumor tissue versus control tissue samples.

Fig. 3. Top common human miRNAs illustrated [11] as detected in corresponding independent analyses from both microarray and RNA-Seq. A total of eight common miRNAs were
highlighted across both methods under the statistical cut-offs previously described [1].

J. Peng et al. / Genomics Data 2 (2014) 285–289

Comparison of datasets
Both targeted (microarray) and untargeted (small RNA-Seq)
approaches were extensively compared in our previously published
manuscript [1]. While only eight dysregulated human miRNAs were
identiﬁed in both the microarray and RNA-Seq analysis (Fig. 3) as statistically signiﬁcant, the overall datasets were comparable. All but three
miRNAs identiﬁed by microarray as signiﬁcantly dysregulated were
also identiﬁed by RNA-Seq, albeit not as signiﬁcant [1]. In addition,
these miRNAs also showed a similar dysregulation: i.e. if identiﬁed as
up-regulated by microarray, they were also identiﬁed as up-regulated
by small RNA-Seq [1].
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